摘要
OBJECTIVE@#To analyze the clinical features and variants of ABCD1 gene in a Chinese pedigree affected with X-linked adrenoleukodystrophy.@*METHODS@#Clinical data of the proband were collected and analyzed. Potential variant of the ABCD1 gene were analyzed by PCR and Sanger sequencing of the proband, his parents and 100 unrelated healthy individuals.@*RESULTS@#The prominent features of the proband included cerebellar and brainstem lesions, along with increased serum level of very-long chain fatty acids. He was found to harbor a hemizygous c.1509delG (p.L504Sfs*54) variant of the ABCD1 gene, for which his mother was heterozygous. The same variant was not detected in his father and 100 healthy controls.@*CONCLUSION@#X-linked adrenoleukodystrophy has a variety of clinical manifestations. Discovery of the c.1509delG (p.L504Sfs*54), as a novel pathogenic variant of the ABCD1 gene, has enabled diagnosis and genetic counseling for this pedigree.
Subject(s)
Female , Humans , Male , Adrenoleukodystrophy/genetics , Asian People/genetics , China , Genetic Testing , Mutation , PedigreeSubject(s)
Humans , Spinocerebellar Degenerations , Cerebellar Ataxia , Adrenoleukodystrophy , Cerebellum摘要
Introduction: Several studies in the literature have evaluated the role of oxidative stress and adjuvant therapies for X-linked adrenoleukodystrophy (X-ALD). Here, we investigated whether n-acetyl-L-cysteine (NAC) and rosuvastatin (RSV) could influence the generation of reactive species, redox status and nitrative stress in fibroblasts from asymptomatic patients with X-ALD. Methods: Skin biopsy samples were cultured and treated for 2 hours (37 °C) with NAC and RSV. Results: X-ALD fibroblasts generated high levels of reactive oxygen species. These levels were significantly lower in fibroblasts treated with NAC and RSV relative to untreated samples. The X-ALD fibroblasts from asymptomatic patients also had higher catalase activity, and only NAC was able to increase enzyme activity in the samples. Conclusions: Our results indicated that NAC and RSV were able to improve oxidative stress parameters in fibroblasts from asymptomatic patients with X-ALD, showing that adjuvant antioxidant therapy may be a promising treatment strategy for asymptomatic patients with this disease. (AU)
Subject(s)
Humans , Male , Female , Acetylcysteine , Oxidative Stress , Adrenoleukodystrophy/therapy , Rosuvastatin Calcium , Fibroblasts摘要
Introduction: X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal metabolic disorder associated with mutations in the ATP-binding cassette sub-family D member1 (ABCD1) gene. Practically all male patients with X-ALD develop adrenocortical insufficiency during childhood and progressive myelopathy and peripheral neuropathy in adulthood. However, some male patients develop a fatal cerebral demyelinating disease named cerebral adrenoleukodystrophy. Although the exact mechanisms underlying brain damage in X-ALD are still poorly elucidated, it is known that hexacosanoic acid (C26:0) accumulation represents a hallmark in the pathogenesis of this disease. In this study, we examined whether an overload of C26:0 injected in Wistar rats was capable of causing behavioral changes in these animals. Methods: Egg lecithin in ethanol was dried under a nitrogen stream and mixed with C26:0 methyl ester. Male Wistar rats at 2-3 weeks of age were obtained from Universidade Federal do Rio Grande do Sul (UFRGS), divided into 8 groups, and submitted to an open field test. We then analyzed line crossings (locomotion and exploration), rearing (orienting and investigatory responses), grooming (anxiety manifestation), and latency to move for each animal. Results: Animals subjected to C26:0 administration presented fewer crossings and rearing episodes and a higher latency to move 45 minutes after C26:0 injection. The present work yields experimental evidence that C26:0, the main accumulated metabolite in X-ALD, can cause behavioral alterations in rats such as the impairment of locomotion and exploratory capabilities, as well as a reduction in orienting and investigatory responses. Conclusion: Although our results are preliminary, they are extremely important for future studies that investigate C26:0 accumulation and locomotor impairment in patients with X-ALD. (AU)
Subject(s)
Animals , Rats , Behavior , Rats, Wistar , Adrenoleukodystrophy , Cerebrum/drug effects , Fatty Acids , Motor Activity/drug effects摘要
ABSTRACT Objective: To describe patients with different phenotypes of X-linked adrenoleukodystrophy: pre-symptomatic, cerebral demyelinating inflammatory adrenoleukodystrophy, adrenomyeloneuropathy and adrenal insufficiency only. Methods: Specific data related to epidemiology, phenotype, diagnosis and treatment of 24 patients with X-linked adrenoleukodystrophy were collected. A qualitative cross-sectional and descriptive-exploratory analysis was performed using medical records from a reference center in Neuropediatrics in Curitiba, Brazil, as well as an electronic questionnaire. Results: The majority (79%) of patients had cerebral demyelinating inflammatory adrenoleukodystrophy, presenting aphasia, hyperactivity and vision disorders as the main initial symptoms. These symptoms appeared, on average, between six and seven years of age. There was a mean delay of 11 months between the onset of symptoms/signs and the diagnosis. Patients sought diagnosis mainly with neuropediatricians, and the main requested tests were dosage of very long chain fatty acids and brain magnetic resonance. Conclusions: All phenotypes of X-linked adrenoleukodystrophy, except for myelopathy in women, were presented in the studied population, which mainly consisted of children and adolescents. Prevalent signs and symptoms registered in the literature were observed. Most of the patients with cerebral demyelinating inflammatory adrenoleukodystrophy were not diagnosed in time for hematopoietic stem cell transplantation.
RESUMO Objetivo: Descrever pacientes com diferentes formas de adrenoleucodistrofia ligada ao X: pré-sintomática, adrenoleucodistrofia inflamatória desmielinizante cerebral, adrenomieloneuropatia e insuficiência adrenal primária. Métodos: Dados específicos relacionados a epidemiologia, fenótipo, diagnóstico e tratamento de 24 pacientes com adrenoleucodistrofia ligada ao X foram coletados. Realizou-se análise qualitativa, transversal e descritivo-exploratória, utilizando prontuários de um centro de referência em neuropediatria de Curitiba, Brasil, além de um questionário eletrônico. Resultados: A maioria (79%) dos pacientes manifestou adrenoleucodistrofia inflamatória desmielinizante cerebral, apresentando afasia, hiperatividade e distúrbios da visão como principais sintomas iniciais, que apareceram, em média, entre seis e sete anos de idade. Houve um atraso médio de 11 meses entre o início das manifestações e o diagnóstico. Os pacientes procuraram diagnóstico principalmente com neuropediatras, e os principais exames solicitados foram dosagem de ácidos graxos de cadeia muito longa e a ressonância magnética de crânio. Conclusões: Todos os fenótipos da adrenoleucodistrofia ligada ao X, exceto mielopatia em mulheres, foram apresentados na amostra estudada, composta principalmente de crianças e adolescentes. Foram observados sinais e sintomas prevalentes na literatura. A maioria dos pacientes com adrenoleucodistrofia inflamatória desmielinizante cerebral não recebeu diagnóstico em tempo hábil para a realização de transplante de medula óssea.
Subject(s)
Humans , Child , Adolescent , Young Adult , Adrenoleukodystrophy/complications , Adrenoleukodystrophy/diagnosis , Adrenoleukodystrophy/therapy , Adrenoleukodystrophy/epidemiology , Phenotype , Brazil/epidemiology , Cross-Sectional Studies摘要
Abstract X-linked adrenoleukodystrophy (X-ALD) represents a group of diseases characterized by the accumulation of very long chain fattyacids (VLCFAs) in the tissues. Its clinical manifestations are usually manifold. Visual changes may be present, but they often appear later in the disease. We describe here the case of a 9-year-old boy with X-ALD, whose first symptom was visual loss, which began at 8 years of age. His ophthalmologic evaluation revealed no alterations. Shortly thereafter, he suffered a head injury. The magnetic resonance imaging of brain revealed findings that led to the suspicion of X-ALD. The plasma VLCFA dosage confirmed this diagnosis. This report aims toshow that in cases of visual loss with a normal ophthalmic examination, a high index of suspicion should be given for conditions suchas X-ALD, since it affects the cortical routes related to vision. Fundoscopy findings appear late in X-ALD.
Resumo A adrenoleucodistrofia ligada ao X (X-ALD) representa um grupo de doenças caracterizadas pelo acúmulo de ácidos graxos de cadeia muito longa (VLCFAs) nos tecidos. Suas manifestações clínicas costumam ser múltiplas. Alterações visuais podem estar presentes, contudo costumam surgir mais tardiamente na doença. Descrevemos aqui o caso de um menino de 9 anos com X-ALD, cujo primeiro sintoma foi perda visual, iniciada aos 8 anos de idade. A sua avaliação oftalmológica não revelou alterações. Pouco tempo depois, ele sofreu um traumatismo craniano. A imagem de ressonância magnética de encéfalo revelou achados que levaram a suspeita de X-ALD. A dosagem dos VLCFAs no plasma confirmou este diagnóstico. Este relato tem como objetivo mostrar que em casos de perda visual com um exame oftalmológico normal, deve-se ter um alto índice de suspeita para condições como a X-ALD, pois a mesma afeta as vias corticais relacionadas à visão. Nessa doença, os achados da fundoscopia aparecem mais tardiamente.
Subject(s)
Humans , Male , Child , Vision Disorders/etiology , Adrenoleukodystrophy/complications , Magnetic Resonance Imaging , Peroxisomal Disorders/complications , Peroxisomal Disorders/diagnosis , Adrenoleukodystrophy/diagnosis , Blindness, Cortical/etiology , Fatty Acids/blood摘要
@#<p><strong>OBJECTIVE:</strong> This study reviewed the profiles and outcomes of patients diagnosed to have the five most common inherited metabolic diseases (IMDs) in the Metabolic Registry of the National Institutes of Health - Institute of Human Genetics (NIH-IHG) from 1999 to 2016.</p><p><br /><strong>METHODS: </strong>The medical records of the patients diagnosed with the following inherited metabolic diseases were reviewed: maple syrup urine disease (MSUD), galactosemia, hyperphenylalaninemias (including classical phenylketonuria, mild hyperphenylalaninemia, and pterin defects), mucopolysaccharidoses (MPS), and adrenoleukodystrophy (ALD).</p><p><br /><strong>RESULTS:</strong> There was a total of 567 patients with IMDs, giving a minimum estimated burden of 1.9 per 100,000 livebirths (1:51,760). Clinical presentations were similar to those reported in literature. Majority of the cases of galactosemia and hyperphenylalaninemias presented with a positive newborn screening result. The local prevalence of MSUD and MPS II were higher compared to international data, which may be explained by reported founder mutations among Filipinos. Majority of the patients with IMDs were diagnosed late leading to preventable developmental delay or intellectual disability and death. Majority of patients with MSUD (80.6%) and MPS (94.7%) had intellectual disability or developmental delay. Mortality was 50.5% among patients with MSUD and 100% among patients with adrenoleukodystrophy.</p><p><br /><strong>CONCLUSION: </strong>There is a diversity of IMDs present in the country. A long-term strategic plan, such as the full implementation of the National Rare Disease Act, is foreseen to improve access to comprehensive healthcare and quality of life of patients with IMDs in the country.</p>
Subject(s)
Humans , Metabolism, Inborn Errors , Maple Syrup Urine Disease , Galactosemias , Mucopolysaccharidoses , Adrenoleukodystrophy , Rare Diseases摘要
OBJECTIVE@#X-linked adrenoleukodystrophy (ALD) is a severe inherited disorder leading to rapid neurological deterioration and premature death. Allogeneic hematopoietic stem cell transplantation (HSCT) is still the only treatment that halts the neurologic symptoms in ALD. However, many patients lack suitable human leukocyte antigen (HLA) matched related donors and must rely on alternative donors for a source of stem cells. The purpose of this study was to explore the outcomes of haploidentical allogeneic stem cell transplantation for ALD patients.@*METHODS@#Between December 2014 and December 2018, eight children with ALD lacking HLA matched related or unrelated donors were treated with haploidentical allogeneic hematopoietic stem cell transplantation. The patients received conditioning regimen with busulfan 9.6 mg/kg, cyclophosphamide 200 mg/kg and fludarabine 90 mg/m2. Graft-versus-host disease (GVHD) prophylaxis consisted of anti-human thymocyte globulin, cyclosporine A, mycophenolate mofetil and short course of methotrexate.@*RESULTS@#All the 8 children received allogeneic stem cell transplants from their fathers. The median age of the recipients was 8 (range: 5-12) years. The median age of the donors was 36 (range: 32-40) years. All the recipients received granulocyte colony-stimulating factor (G-CSF) mobilized bone marrow and peripheral blood-derived stem cells. The median number of total mononuclear cells dose and CD34+ dose was 10.89 (range: 9.40-12.16)×108/kg and 7.06 (range: 0.74-7.80)×106/kg, respectively. Neutrophil engraftment occurred a median of 11 days (range:8-13 days) after transplantation. Platelet engraftment occurred a median of 10 days (range:8-12 days) after transplantation. All the patients achieved complete donor chimerism at the time of engraftment. Four patients had grades II-IV acute GVHD and 1 had chronic graft-versus-host disease. No severe chronic GVHD occurred. Among all the children, 2 had cytomegalovirus (CMV) DNAemia and 2 Epstein-Barr virus (EBV) DNAemia. Overall, seven of them survived and had no major complications related to transplantation. One died of cerebral hernia after epilepsy 125 days after transplantation.@*CONCLUSION@#The preliminary observation demonstrates that haploidentical allogeneic stem cell transplantation with this novel regimen could successfully achieve full donor chimerism in ALD patients. According to our experience, haploidentical allogeneic hematopoietic stem cell transplantation is safe and feasible in the treatment of X-linked adrenoleukodystrophy.
Subject(s)
Adult , Child , Child, Preschool , Humans , Adrenoleukodystrophy/therapy , Bone Marrow Transplantation , Chromosomes, Human, X , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Transplantation Conditioning摘要
OBJECTIVE@#To explore the genetic basis for a pedigree affected with X-linked adrenoleukodystrophy presenting as spastic paraplegia of the lower limbs.@*METHODS@#Genomic DNA was extracted from peripheral blood samples of the patient and his mother. Potential variant was detected with a panel for genes associated with spastic paraplegia. Candidate variant was verified by PCR and Sanger sequencing.@*RESULTS@#Both the proband and his mother presented with walking difficulty. A previously known variant, c.623T to A (p.V208E), was identified in the ABCD1 gene mapped on chromosome X in both.@*CONCLUSION@#X-link adrenoleukodystrophy should be taken into account as a possible diagnosis for this pedigree.
Subject(s)
Female , Humans , Male , ATP Binding Cassette Transporter, Subfamily D, Member 1 , Genetics , Adrenoleukodystrophy , Genetics , Genetic Testing , Pedigree , Spastic Paraplegia, Hereditary摘要
RESUMEN La adrenoleucodistrofia, el trastorno peroxisomal más frecuente, es una condición genética ligada al cromosoma X en la cual se presenta un defecto en la betaoxidación de los ácidos grasos de cadena muy larga dentro del perosixoma, con su consecuente acumulación en diferentes tejidos, lo que lleva a manifestaciones principalmente neurológicas y endocrinológicas. Existe una variabilidad fenotípica de acuerdo con la edad de presentación que incluye la forma adulta llamada adrenomieloneuropatía. A continuación se presenta el caso de un hombre adulto, con múltiples consultas a los servicios de urgencias en relación con síntomas medulares dorsales, con evidencia de insuficiencia suprarrenal y paraclínicos que soportan el diagnóstico de adrenomieloneuropatía.
SUMMARY Adrenoleukodystrophy, the most common peroxisomal disorder, is a genetic condition linked to the X chromosome in which a defect of beta oxidation of very long chain fatty acids occurs within the perosixome with its consequent accumulation in different tissues leading to mainly neurological and endocrinological manifestations; there is a phenotypic variability according to the age of presentation including the adult form called adrenomyeloneuropathy. This case report refers to an adult male with multiple visits to emergency departments in relation to dorsal spinal symptoms with evidence of adrenal insufficiency and paraclinical support the diagnosis of adrenomyeloneuropathy.
Subject(s)
Adrenal Insufficiency , Adrenoleukodystrophy摘要
Introducción: La adrenomieloneuropatía es una enfermedad peroxisomal, con patrón de herencia ligada al sexo. Es una variedad fenotípica de la adrenoleucodistrofia ligada al cromosoma X, esta última es también causa de insuficiencia adrenal. La adrenomieloneuropatía no pura cursa con insuficiencia adrenal. El diagnóstico de la enfermedad se hace por dosificación de ácidos grasos de cadena muy larga en suero. Para el diagnóstico de los fenotipos se emplean datos clínicos, anamnesis, datos de laboratorio y de imagen. Objetivo:Presentar un caso de adrenoleucodistrofia ligada al cromosoma X, fenotipo adrenomieloneuropatía, evaluado por reibergrama. Presentación del caso: Se presenta un caso de adrenomieloneuropatía e insuficiencia adrenal en un paciente masculino de 4 años de evolución, el cual ha sido hospitalizado en el Hospital Clínico-Quirúrgico Dr. Miguel Enríquez de La Habana, Cuba, en 2016 por un proceso respiratorio. Se diagnostica adrenoleucodistrofia ligada al cromosoma X, para identificar las variantes fenotípicas se tuvieron en cuenta los exámenes de laboratorio, técnicas imagenológicas, método clínico y una adecuada anamnesis. Conclusiones: El reibergrama puede contribuir al diagnóstico diferencial entre los fenotipos de la ADL-X y a la comprensión de la respuesta neuroinmunológica en esta enfermedad tal y como se demuestra en este caso(AU)
Introduction: Adrenomyeoloneuropathy is a peroxisomal disease with a sex-linked pattern of inheritance. It is a phenotypic variety of X-linked adrenoleukodystrophy; this last one is also a cause of adrenal insufficiency. Non-pure adrenomyeoloneuropathy occurs with adrenal insufficiency. The diagnosis of the disease is made by dosing very long chain fatty acids in serum. Clinical data, anamnesis, laboratory exams and imaging data are used for the diagnosis of phenotypes. Objective: To present a case of X-linked adrenoleukodystrophy, adrenomyeoloneuropathy phenotype, evaluated by Reibergram. Case presentation: We present a case of adrenomyeoloneuropathy and adrenal insufficiency in a male patient of 4 years of evolution who was admitted to Dr. Miguel Enríquez Clinical and Surgical Hospital, Havana, Cuba, 2016 because he was suffering from a respiratory process. The diagnosis of X-linked adrenoleukodystrophy was made. Laboratory exams, imaging techniques, the clinical method, and an adequate anamnesis were taken into account to for the identification of phenotypic variants. Conclusions: Reibergram can contribute to the differential diagnosis between ADL-X phenotypes and the understanding of the neuroimmunological response in this disease, as it is demonstrated in this case(AU)
Subject(s)
Humans , Male , Middle Aged , X Chromosome/genetics , Adrenoleukodystrophy/diagnosis , Adrenoleukodystrophy/epidemiology , Adrenal Insufficiency/complications摘要
Spastic paraparesis is caused by various etiologies such as autoimmune, infection, genetic and metabolic disorder. Adrenomyeloneuropathy (AMN) is very rare but one of important causes in spastic paraparesis. We experienced a patient presenting with adult-onset progressive spastic paraparesis, who was diagnosed as AMN with hemizygous c.431C>T (p.A144V), a novel mutation in exon1. The level of very long chain fatty acid should be included in diagnostic work-up for patients presenting with adult-onset progressive spastic paraparesis.
Subject(s)
Humans , Adrenoleukodystrophy , Muscle Spasticity , Paraparesis, Spastic摘要
La adrenoleucodistrofia ligada al X es el trastorno peroxisomal más común. Se debe a mutaciones en el gen ABCD1, lo que ocasiona un acúmulo de ácidos grasos saturados de cadena muy larga en el suero, la corteza adrenal y la sustancia blanca del sistema nervioso central. La clínica se caracteriza por deterioro neurològico e insuficiencia suprarrenal con un pronóstico devastador. Se presenta un primer caso clínico de adrenoleucodistrofia ligada al X con evolución fatal que permitió identificar a dos familiares asintomáticos e instaurar un tratamiento preventivo. Aunque, en la actualidad, no existe un tratamiento curativo definitivo, hay que destacar la importancia del estudio familiar de pacientes en situación de riesgo para poder instaurar un tratamiento preventivo precoz y dar un asesoramiento genético adecuado.
X-linked adrenoleukodystrophy is the most common peroxisomal disorder. This disease is caused by a defect in the ABCD1 gen. Saturated very long chain fatty acids are accumulated in serum, adrenal cortex and central nervous system white matter. The clinical spectrum is characterized by progressive neurological dysfunction and adrenal insufficiency with a devastating prognosis. We report a first case of X-linked adrenoleukodystrophy with fatal evolution which identified two asymptomatic family members and established a preventive treatment. Although there is no definitive cure, we stress the importance of family study and evaluation of the individual in situation of risk to establish an early preventive treatment and to give in each particular situation suitable professional advice.
Subject(s)
Humans , Male , Infant , Child, Preschool , Child , Adrenoleukodystrophy/diagnosis , Adrenoleukodystrophy/genetics , Early Diagnosis摘要
@#Background. X-linked adrenoleukodystrophy (X-ALD) is a progressive genetic disorder affecting the metabolism of very long chain fatty acids in the adrenal glands, spinal cord and white matter of the nervous system. It is an inherited metabolic storage disease whereby a defect in a specific enzyme results in the accumulation of very long-chain fatty acids (VLCFA) that are harmful to some cells and organs. VLCFA analysis for confirmation of X-linked adrenoleukodystrophy is one of the most requested tests among the send-out laboratory services of the Biochemical Genetics Laboratory at the Institute of Human Genetics. This paper aims to review the clinical characteristics and the results of the VLCFA analysis of the patients whose samples we received for testing.Methods. Overseas tests samples received by the Biochemical Genetics Laboratory for VLCFA from 2002-2016 were included. The details of the patients were collated in an overseas tests database and was the main source of the data for this study. The results of the VLCFA tests sent to the Kennedy Krieger Institute and The Children’s Hospital at Westmead were inputted into the said database. Descriptive statistics was utilized in order to examine the clinical and biochemical data of the patients.Results. The results showed that out of the 54 samples submitted to our laboratory, 19 (35%) of the samples received from male patients suspected to have X-ALD yielded positive results and another 10 (19%) females were found to be carriers. Visual defect followed by deteriorating mental status were the most frequent indications for VLCFA testing. Conclusion. Having a significant diagnostic yield of 54%, early diagnosis of X-linked adrenoleukodystrophy in our population is important so that proper management that could prevent the progression of the disease could be timely instituted.
Subject(s)
Metabolism, Inborn Errors , Peroxisomal Disorders , Adrenoleukodystrophy摘要
Introduction: Recent evidence shows that oxidative stress seems to be related with the pathophysiology of X-linked adrenoleukodystrophy (X-ALD), a neurodegenerative disorder. Methods: In the present study, the in vitro effect of N-acetyl-L-cysteine (NAC) on glutathione (GSH) and sulfhydryl levels in X-ALD patients was evaluated. Results: A significant reduction of GSH and sulfhydryl content was observed in X-ALD patients compared to the control group. Furthermore, 5 mM of NAC, in vitro, led to an increase in GSH content and sulfhydryl groups in these patients. Conclusion: These data probably indicate that an adjuvant therapy with the antioxidant NAC could improve the oxidative imbalance in X-ALD patients(AU)
Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Acetylcysteine/pharmacology , Adrenoleukodystrophy/physiopathology , Glutathione/deficiency , Sulfhydryl Compounds/metabolism , Adrenoleukodystrophy/drug therapy , Oxidation-Reduction/drug effects , Oxidative Stress摘要
La adrenoleucodistrofia ligada al X (X-ALD), trastorno genético progresivo que afecta la sustancia blanca del SNC y la corteza suprarrenal, causa desde insuficiencia adrenal aislada y mielopatia lentamente progresiva hasta desmielinización cerebral devastadora. Presentamos un paciente masculino, 21 años de edad, tabaquista, con trastorno de la marcha de un año de evolución, paraparesia espástica e hiperreflexia en miembros inferiores. El análisis del líquido cefalorraquídeo (LCR) reveló proteinorraquia elevada, resultados negativos de bandas oligoclonales y virus Epstein Barr. Niveles de cortisol, ACTH, ácidos grasos de cadena muy larga en suero, fueron anormales. La RNM cerebral evidenció lesiones en sustancia blanca en región parietooccipital bilateral, comprometiendo el esplenio del cuerpo calloso, que realzaban con gadolinio. En RNM de columna cervical se observó lesión hiperintensa en secuencia T2 a nivel C7. Fue tratado con reemplazo adrenal. Presentamos un caso de X-ALD de inicio en adulto, con retraso en el diagnóstico debido a recursos limitados. Palabras claves: adrenoleucodistrofia ligada al X, paraparesia espástica, ácidos grasos de cadena muy larga, adrenomieloneuropatia
X- Linked adrenoleukodystrophy (X-ALD) is a progressive genetic disorder that affects CNS white matter and adrenal gland cortex, and causes from isolated adrenocortical insufficiency and slowly progressive myelopathy to devastating cerebral demyelination. We present a 21 years old male patient, smoker, with one year history of gradually progressive trouble walking, unsteady gait, asymmetric spastic paraparesis, lower extremity deep tendon reflexes were increased. Cerebrospinal fluid (CSF) analysis revealed elevated CSF protein, CSF oligoclonal bands and Epstein Barr virus negative results. Basal cortisol, ACTH and very-long- chain fatty acids in plasma with abnormal results. All other laboratory tests were normal. Cerebral MRI showed parietooccipital white matter abnormalities involving the splenium of the callosum that enhanced with gadolinium. Cervical spinal cord MRI showed a short-segment T2 hyperintense lesion at C7. He was treated with adrenal replacement. We present a case of adult onset X-ALD and diagnostic delay owed to limited resources
Subject(s)
Humans , Male , Young Adult , Spinal Cord Diseases/diagnosis , Central Nervous System , Adrenocorticotropic Hormone/deficiency , Paraparesis, Spastic/pathology , Fatty Acids , Tendons , Cervical Vertebrae , Demyelinating Diseases , Adrenoleukodystrophy/diagnosis , Adrenoleukodystrophy/genetics , Genetic Diseases, Inborn/diagnosis摘要
ABSTRACT Hematopoietic stem cell transplantation (HSCT) is the only available treatment for the neurological involvement of disorders such as late-onset metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I-Hurler (MPS-IH), and X-linked cerebral adrenoleukodystrophy (CALD). Objective To describe survival and neurological outcomes after HSCT for these disorders. Methods Seven CALD, 2 MLD and 2 MPS-IH patients underwent HSCT between 2007 and 2014. Neurological examinations, magnetic resonance imaging, molecular and biochemical studies were obtained at baseline and repeated when appropriated. Results Favorable outcomes were obtained with 4/5 related and 3/6 unrelated donors. Two patients died from procedure-related complications. Nine transplanted patients were alive after a median of 3.7 years: neurological stabilization was obtained in 5/6 CALD, 1/2 MLD, and one MPS-IH patient. Brain lesions of the MPS-IH patient were reduced four years after HSCT. Conclusion Good outcomes were obtained when HSCT was performed before adulthood, early in the clinical course, and/or from a related donor.
RESUMO O transplante de células tronco hematopoiéticas (TCTH) é o único tratamento disponível para o envolvimento neurológico de doenças como a leucodistrofia metacromática (MLD), a mucopolissacaridose tipo I-Hurler (MPS-IH) e a adrenoleucodistrofia (CALD). Objetivos Descrever a sobrevida e os desfechos neurológicos após o TCTH nessas doenças. Métodos Sete pacientes CALD, 2 MLD e 2 MPS-IH realizaram TCTH entre 2007 e 2014. Avaliações neurológicas, ressonância nuclear magnética e estudos bioquímicos e moleculares foram feitos no baseline e repetidos quando apropriado. Resultados Desfechos favoráveis foram obtidos em 4/5 TCTH de doadores relacionados e em 3/6 não relacionados. Dois pacientes faleceram de complicações do procedimento. Nove transplantados sobreviveram após uma mediana de 3,7 anos: estabilização neurológica foi obtida em 5/6 CALD, ½ MLD e em um caso MPS-IH. As lesões encefálicas de um caso MPS-IH reduziram-se quatro anos após o TCTH. Conclusão Bons desfechos foram obtidos quando o TCTH foi feito antes da vida adulta, cedo no curso clínico e/ou a partir de um doador relacionado.
Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Adult , Young Adult , Mucopolysaccharidosis I/surgery , Hematopoietic Stem Cell Transplantation/mortality , Adrenoleukodystrophy/surgery , Leukodystrophy, Metachromatic/surgery , Pedigree , Tissue Donors , Brain/pathology , Brain/diagnostic imaging , Brazil/epidemiology , Magnetic Resonance Imaging , Retrospective Studies , Treatment Outcome , Mucopolysaccharidosis I/genetics , Mucopolysaccharidosis I/mortality , Age of Onset , Adrenoleukodystrophy/genetics , Adrenoleukodystrophy/mortality , Transplantation Conditioning/methods , White Matter/diagnostic imaging , Leukodystrophy, Metachromatic/genetics , Leukodystrophy, Metachromatic/mortality摘要
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) has been established as an important curative method in genetic rare diseases in children. However, adverse effects have been obstacles for successful outcomes. This study aims to review the transplant outcomes of genetic rare diseases over the last 2 decades, to analyze the prognostic factors that may affect outcome, and to suggest future perspective of HSCT in these diseases. METHODS: Seventeen patients younger than 18 years who were transplanted at Department of Pediatrics, Chonnam National University Hospital and Chonnam National University Hwasun Hospital from 1996 to 2015 were retrospectively reviewed. Outcomes were analyzed by donor source, intensity of conditioning [myeloablative conditioning (MAC) vs. reduced-intensity conditioning (RIC)], and disease type. RESULTS: The 5-year Kaplan-Meier overall survival (OS), and event-free survival (EFS) was 64.7±14.3% and 52.9±12.9%, respectively. Among subgroups, the 5-year OS was 61.5±15.8% after RIC as compared to 28.6±17.1% after MAC (P=0.27). The 5-year EFS was 60.0±25.0% after matched sibling donor transplants, 62.5±20.4% after mismatched related/unrelated bone marrow/peripheral blood stem cell transplants, and 28.6±17.1% after unrelated umbilical cord blood transplants, respectively. The 5-year OS according to disease type was as follows: 60.0±21.9% for Fanconi anemia, 50.0±25.0% for familial hemophagocytic lymphohisticytosis. All patients with primary immunodeficiency survived, but none with adrenoleukodystrophy. CONCLUSION: Although definitive conclusions cannot be drawn due to the limited number of cases, RIC may be preferred in select, genetic rare diseases. Better strategies are required to improve outcomes after cord blood transplantation. Moreover, special attention should be given to minimize late complications in children.
Subject(s)
Child , Humans , Adrenoleukodystrophy , Disease-Free Survival , Fanconi Anemia , Fetal Blood , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells , Methods , Pediatrics , Rare Diseases , Retrospective Studies , Siblings , Stem Cells , Tissue Donors摘要
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) has been established as an important curative method in genetic rare diseases in children. However, adverse effects have been obstacles for successful outcomes. This study aims to review the transplant outcomes of genetic rare diseases over the last 2 decades, to analyze the prognostic factors that may affect outcome, and to suggest future perspective of HSCT in these diseases.METHODS: Seventeen patients younger than 18 years who were transplanted at Department of Pediatrics, Chonnam National University Hospital and Chonnam National University Hwasun Hospital from 1996 to 2015 were retrospectively reviewed. Outcomes were analyzed by donor source, intensity of conditioning [myeloablative conditioning (MAC) vs. reduced-intensity conditioning (RIC)], and disease type.RESULTS: The 5-year Kaplan-Meier overall survival (OS), and event-free survival (EFS) was 64.7±14.3% and 52.9±12.9%, respectively. Among subgroups, the 5-year OS was 61.5±15.8% after RIC as compared to 28.6±17.1% after MAC (P=0.27). The 5-year EFS was 60.0±25.0% after matched sibling donor transplants, 62.5±20.4% after mismatched related/unrelated bone marrow/peripheral blood stem cell transplants, and 28.6±17.1% after unrelated umbilical cord blood transplants, respectively. The 5-year OS according to disease type was as follows: 60.0±21.9% for Fanconi anemia, 50.0±25.0% for familial hemophagocytic lymphohisticytosis. All patients with primary immunodeficiency survived, but none with adrenoleukodystrophy.CONCLUSION: Although definitive conclusions cannot be drawn due to the limited number of cases, RIC may be preferred in select, genetic rare diseases. Better strategies are required to improve outcomes after cord blood transplantation. Moreover, special attention should be given to minimize late complications in children.